Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

News Daily News

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

Michael O'Riordan

November 09, 2016

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Daily News

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Todd Neale

June 22, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

The Ups and Downs of Statin Adherence Around Acute MI Hospitalization

Todd Neale

May 25, 2016

News Features

Requiem for a Heavyweight: Big Brand Statin Era Comes to a Close as Crestor Heads Off-Patent

Michael O'Riordan

May 03, 2016

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Daily News

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Michael O'Riordan

December 15, 2015

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Industry News

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

November 23, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Daily News

IMPROVE-IT结果发布：对于向他汀类疗法中添加依泽替米贝是否有帮助进行了热烈的辩论

Yael L. Maxwell

June 05, 2015

News Daily News

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

Yael L. Maxwell

June 05, 2015

News Daily News

El Controvertido Ezetimibe Ayuda cuando se Incorpora al Tratamiento con Estatinas

Yael L. Maxwell

June 05, 2015

News Daily News

NSTE-ACS Patients With Inflammation Gain the Most Kidney Protection From Statin Pretreatment

Yael L. Maxwell

December 15, 2014

Advertisement

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

The Ups and Downs of Statin Adherence Around Acute MI Hospitalization

Requiem for a Heavyweight: Big Brand Statin Era Comes to a Close as Crestor Heads Off-Patent

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

IMPROVE-IT结果发布：对于向他汀类疗法中添加依泽替米贝是否有帮助进行了热烈的辩论

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

El Controvertido Ezetimibe Ayuda cuando se Incorpora al Tratamiento con Estatinas

NSTE-ACS Patients With Inflammation Gain the Most Kidney Protection From Statin Pretreatment

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content